UPDATE:
The FDA announced that it will push back its decision on whether to approve the reversal agent AndexXa to May 4, 2018. The original review date was set for February 3, 2018, but the FDA wanted to consider additional information it had requested from Portola, the drug's manufacturer.
(12/28/17).
Risk of Bleeding … [Read more...]

On June 23, 2017, a new anticoagulant drug called BevyxXa (betrixaban) was approved by the FDA for the prevention of venous thromboembolism and pulmonary embolism.
This drug acts as a direct Factor Xa inhibitor, similar to the other anticoagulant drugs Eliquis, Savaysa, and Xarelto.
Unlike the anticoagulant Pradaxa, which is a direct … [Read more...]

There in an ongoing debate amongst medical professionals concerning the effectiveness and safety of warfarin in comparison to the non–vitamin K antagonist oral anticoagulants (NOACs)--such as Eliquis, Xarelto, Savaysa, and Pradaxa--for patients with atrial fibrillation.
According to the Healio Cardiology today article, "Merits of warfarin, newer … [Read more...]

In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis (apixaban).
Earlier this month the medical journal Chest published this article, “Direct comparison of dabigatran, rivaroxaban, and apixaban for … [Read more...]

Recently, controversy has arisen over what to call the novel oral anticoagulant class of drugs, which includes Pradaxa, Xarelto, Savaysa, and Eliquis. The article "NOAC, DOAC, or TSOAC: What Should We Call Novel Oral Anticoagulants?" provides some interesting information about the different sides of this debate.
Here is a list of the possible … [Read more...]

Savaysa (edoxaban) is a factor Xa inhibitor which was approved by the FDA in 2015. Savaysa has the following so-called “indications” or approved uses:
To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; and,
For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following … [Read more...]

The following Factor Xa inhibitors, which serve as blood-thinner drugs, are being used by an increasing number of patients for stroke prevention and for treatment of deep vein thrombosis and pulmonary embolism:
Eliquis (apixaban) from Pfizer/Bristol-Myers Squibb;
Xarelto (rivaroxaban) from Bayer/Johnson & Johnson; and,
Savaysa … [Read more...]

According to a Patient-Centered Outcomes Research Institute (PCORI) press release from earlier this month, the PCORI Board of Governors approved $6.5 million for research to compare the potential benefits and harms of popular anticoagulant drugs.
The study will include the older anticoagulant, Coumadin (warfarin), as well as the newer "novel … [Read more...]

I think it is interesting how this recent Healio – HemOnc Today news reports, “Edoxaban safe, effective for extended prevention of recurrent VTE”, ends by focusing on the continuing lack of any FDA-approve antidote for Savaysa, as well as Eliquis and Xarelto.
The growing availability of agents for the reversal of bleeding caused by direct oral … [Read more...]

Attorney Tom Lamb

Mr. Lamb is recognized by other lawyers as practicing law at the highest level of professional experience in terms of legal ability and ethical standards — which is indicated by an AV® Preeminent™ 5.0 out of 5 rating (highest classification) rating from the Martindale-Hubbell® Lawyer Directory.

More importantly, he received the Martindale-Hubbell® Client Distinction Award, which recognizes excellence for: